09 April 2026
: Case report 
Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report
Unusual clinical course, Unusual or unexpected effect of treatment
A. Maria Vromans
ABEF 1*, Maria Constantinou ABEF 2
DOI: 10.12659/AJCR.950432
Am J Case Rep 2026; 27:e950432
Figure 2 Change in clinical and radiographic disease on immunotherapy. (A) On nivolumab-relatlimab; (B) Peritoneal metastases on nivolumab-relatlimab; (C) Lung metastasis on nivolumab-relatlimab; (D) After cycle 1 of ipilimumab-nivolumab; (E) Regression of peritoneal metastases after cycle 1 of ipilimumab-nivolumab; (F) Regression of lung metastasis after cycle 1 of ipilimumab-nivolumab; (G) One month after cycle 4 of ipilimumab-nivolumab; (H) After 1 year on maintenance nivolumab.